Skip to main content

Table 4 Resource use by predictive biomarker testing status in Italy, Spain, Germany, and Australia

From: Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

 

Italy

(N = 174)

Spain

(N = 202)

Germany

(N = 139)

Australia

(N = 208)

EGFR/ALK tested

Not tested

EGFR/ALK tested

Not tested

EGFR/ALK tested

Not tested

EGFR/ALK tested

Not tested

Pos

Neg/Unk

Pos

Neg/Unk

Pos

Neg/Unk

Pos

Neg/Unk

First-line therapy

N = 22

N = 66

N = 86

N = 24

N = 121

N = 57

N = 21

N = 55

N = 63

N = 31

N = 95

N = 82

No. inpatient staysa

13

26

36

13

72

28

17

49

74

40

209

78

 Hospital

13 (100)

26 (100)

36 (100)

13 (100)

71 (99)

28 (100)

17 (100)

49 (100)

74 (100)

35 (88)

175 (84)

74 (95)

 Hospice

0

0

0

0

1 (1)

0

0

0

0

5 (13)

34 (16)

4 (5)

No. hospitalizationsb

13

26

36

13

71

28

15

52

85

35

177

74

 Normal ward

13 (100)

26 (100)

35 (97)

13 (100)

71 (100)

28 (100)

15 (100)

48 (92)

72 (85)

35 (100)

175 (99)

74 (100)

 ICU

0

0

1 (3)

0

0

0

0

4 (8)

13 (15)

0

2 (1)

0

No. hospitalizations with LOSc

13

25

35

13

70

28

17

49

74

35

173

73

 Mean (SD) days

4.5 (4.2)

7.8 (10.0)

5.4 (6.9)

7.5 (6.4)

8.8 (5.8)

9.1 (5.9)

13.6 (12.4)

9.7 (12.3)

7.4 (10.1)

3.5 (5.6)

4.6 (4.8)

5.2 (7.5)

 Median (range)

4 (1–14)

5 (3–50)

1 (1–26)

6 (2–27)

7 (1–28)

7 (1–26)

9 (1–32)

4 (1–32)

3 (1–32)

1 (1–33)

3 (1–27)

3 (1–48)

Outpatient visits, nd

19

63

64

21

92

32

11

25

32

29

93

73

 Mean (SD) visits

9.1 (8.4)

8.9 (8.3)

5.7 (3.8)

9.4 (9.7)

11.8 (12.8)

7.8 (7.1)

16.0 (10.7)

10.6 (9.7)

7.6 (9.7)

26.7 (30.3)

12.9 (12.4)

7.8 (6.9)

 Median (range)

8 (1–35)

6 (1–34)

5 (1–17)

6 (1–42)

9 (1–58)

6 (1–23)

13 (2–31)

7 (1–41)

3 (1–33)

21 (1–105)

9 (1–57)

6 (1–33)

No. outpatient visits

173

562

367

198

1089

250

176

266

242

774

1203

569

Second-line therapy

N = 14

N = 41

N = 46

N = 14

N = 62

N = 20

N = 14

N = 27

N = 23

N = 22

N = 66

N = 40

No. inpatient staysa

3

5

5

10

33

6

14

13

12

20

51

18

 Hospital

3 (100)

5 (100)

5 (100)

8 (80)

33 (100)

6 (100)

14 (100)

13 (100)

12 (100)

20 (100)

49 (96)

18 (100)

 Hospice

0

0

0

2 (20)

0

0

0

0

0

0

2 (4)

0

No. hospitalizationsb

3

5

5

8

33

6

14

13

12

20

49

18

 Normal ward

3 (100)

5 (100)

5 (100)

8 (100)

33 (100)

6 (100)

14 (100)

13 (100)

12 (100)

20 (100)

49 (100)

18 (100)

 ICU

0

0

0

0

0

0

0

0

0

0

0

0

No. hospitalizations with LOSc

3

5

5

8

32

6

14

13

12

20

49

18

 Mean (SD) days

8.3 (1.2)

9.8 (4.3)

3.8 (4.4)

12.3 (5.3)

10.2 (5.4)

10.0 (4.5)

10.3 (10.5)

7.0 (11.1)

8.2 (6.1)

4.7 (3.4)

5.6 (7.4)

6.3 (4.7)

 Median (range)

9 (7–9)

9 (4–15)

1 (1–11)

14 (5–17)

10 (3–19)

11 (2–15)

6 (1–32)

1 (1–32)

8 (1–19)

4 (1–9)

3 (1–44)

6 (2–21)

Outpatient visits, nd

13

34

25

9

41

12

12

13

10

18

62

22

 Mean (SD) visits

11.5 (12.6)

5.8 (5.9)

6.1 (3.8)

8.3 (4.2)

6.6 (4.8)

7.0 (3.9)

8.2 (10.4)

4.7 (4.2)

6.1 (4.4)

7.3 (5.3)

8.6 (7.1)

5.2 (4.3)

 Median (range)

6 (1–41)

3 (1–25)

6 (1–16)

7 (3–15)

6 (1–17)

8 (1–12)

4 (1–30)

2 (1–12)

7 (1–11)

6 (1–20)

6 (1–26)

4 (1–17)

No. outpatient visits

149

196

153

75

269

84

98

61

61

131

533

115

  1. aTotal number of inpatient stays, defined as one or more nights in a hospital or hospice
  2. bTotal number of hospitalizations, not including hospice stays
  3. cTotal number of hospitalizations with non-missing data regarding length of stay (LOS)
  4. dNumber of patients who had ≥1 outpatient visits
  5. ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, LOS length of stay, Neg/Unk negative/unknown, No. number of, OP outpatient, Pos positive
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us